Lixte Biotechnology Holdings Stock Debt To Equity

LIXTW Stock  USD 0.03  0  2.86%   
Lixte Biotechnology Holdings fundamentals help investors to digest information that contributes to Lixte Biotechnology's financial success or failures. It also enables traders to predict the movement of Lixte Stock. The fundamental analysis module provides a way to measure Lixte Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lixte Biotechnology stock.
Last ReportedProjected for Next Year
Debt To Equity(0.28)(0.29)
Debt To Equity is likely to drop to -0.29 in 2025.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Lixte Biotechnology Holdings Company Debt To Equity Analysis

Lixte Biotechnology's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

Current Lixte Biotechnology Debt To Equity

    
  -0.29  
Most of Lixte Biotechnology's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lixte Biotechnology Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Lixte Debt To Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Lixte Biotechnology is extremely important. It helps to project a fair market value of Lixte Stock properly, considering its historical fundamentals such as Debt To Equity. Since Lixte Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lixte Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lixte Biotechnology's interrelated accounts and indicators.
1.0-0.98-0.870.31.0-0.470.440.87-0.13-0.720.520.930.970.98-0.42
1.0-0.98-0.860.261.0-0.470.420.87-0.14-0.720.50.930.980.98-0.41
-0.98-0.980.83-0.25-0.980.4-0.44-0.880.170.73-0.4-0.91-0.97-0.970.24
-0.87-0.860.83-0.5-0.870.43-0.51-0.780.070.73-0.79-0.88-0.83-0.840.44
0.30.26-0.25-0.50.30.040.660.320.32-0.060.490.310.210.23-0.16
1.01.0-0.98-0.870.3-0.460.440.87-0.13-0.720.510.930.970.98-0.41
-0.47-0.470.40.430.04-0.460.13-0.520.120.23-0.43-0.54-0.49-0.510.46
0.440.42-0.44-0.510.660.440.130.290.31-0.540.260.410.410.4-0.05
0.870.87-0.88-0.780.320.87-0.520.29-0.08-0.550.510.930.890.9-0.19
-0.13-0.140.170.070.32-0.130.120.31-0.080.17-0.08-0.08-0.08-0.080.08
-0.72-0.720.730.73-0.06-0.720.23-0.54-0.550.17-0.4-0.73-0.71-0.710.28
0.520.5-0.4-0.790.490.51-0.430.260.51-0.08-0.40.570.440.48-0.62
0.930.93-0.91-0.880.310.93-0.540.410.93-0.08-0.730.570.930.94-0.32
0.970.98-0.97-0.830.210.97-0.490.410.89-0.08-0.710.440.931.0-0.29
0.980.98-0.97-0.840.230.98-0.510.40.9-0.08-0.710.480.941.0-0.35
-0.42-0.410.240.44-0.16-0.410.46-0.05-0.190.080.28-0.62-0.32-0.29-0.35
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Competition

Lixte Total Stockholder Equity

Total Stockholder Equity

4.82 Million

At this time, Lixte Biotechnology's Total Stockholder Equity is fairly stable compared to the past year.

Did you try this?

Run Positions Ratings Now

   

Positions Ratings

Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Lixte Fundamentals

About Lixte Biotechnology Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Lixte Biotechnology Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lixte Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lixte Biotechnology Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lixte Stock Analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.